Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Immunotherapy Drugs for Multiple Myeloma market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Immunotherapy Drugs for Multiple Myelomamarket, defines the market attractiveness level of Immunotherapy Drugs for Multiple Myeloma market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Immunotherapy Drugs for Multiple Myeloma industry, describes the types of Immunotherapy Drugs for Multiple Myeloma market, the applications of major players and the market size, and deeply analyzes the current situation of the global Immunotherapy Drugs for Multiple Myeloma market and the development prospects and opportunities of Immunotherapy Drugs for Multiple Myeloma industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Immunotherapy Drugs for Multiple Myeloma market in Chapter 13.
By Player:
Sumitomo
Roche
Schering-Plough
Merck
Tonghua Dongbao Pharmaceutical
Chiron
Glaxo
Biogen
By Type:
INF-α
IL-6
Rituximab
Other
By End-User:
Hospital
Drug Center
Clinic
Other
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Immunotherapy Drugs for Multiple Myeloma Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Immunotherapy Drugs for Multiple Myeloma Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Immunotherapy Drugs for Multiple Myeloma Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Immunotherapy Drugs for Multiple Myeloma Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Immunotherapy Drugs for Multiple Myeloma Market Analysis and Outlook to 2022
-
7.1 Global Immunotherapy Drugs for Multiple Myeloma Consumption (2017-2022)
-
7.2 United States Immunotherapy Drugs for Multiple Myeloma Consumption (2017-2022)
-
7.3 Europe Immunotherapy Drugs for Multiple Myeloma Consumption (2017-2022)
-
7.4 China Immunotherapy Drugs for Multiple Myeloma Consumption (2017-2022)
-
7.5 Japan Immunotherapy Drugs for Multiple Myeloma Consumption (2017-2022)
-
7.6 India Immunotherapy Drugs for Multiple Myeloma Consumption (2017-2022)
-
7.7 South Korea Immunotherapy Drugs for Multiple Myeloma Consumption (2017-2022)
8 Region and Country-wise Immunotherapy Drugs for Multiple Myeloma Market Analysis and Outlook to 2028
-
8.1 Global Immunotherapy Drugs for Multiple Myeloma Consumption Forecast (2022-2028)
-
8.2 United States Immunotherapy Drugs for Multiple Myeloma Consumption Forecast (2022-2028)
-
8.3 Europe Immunotherapy Drugs for Multiple Myeloma Consumption Forecast (2022-2028)
-
8.4 China Immunotherapy Drugs for Multiple Myeloma Consumption Forecast (2022-2028)
-
8.5 Japan Immunotherapy Drugs for Multiple Myeloma Consumption Forecast (2022-2028)
-
8.6 India Immunotherapy Drugs for Multiple Myeloma Consumption Forecast (2022-2028)
-
8.7 South Korea Immunotherapy Drugs for Multiple Myeloma Consumption Forecast (2022-2028)
9 Global Immunotherapy Drugs for Multiple Myeloma Market Outlook by Types and Applications to 2022
-
9.1 Global Immunotherapy Drugs for Multiple Myeloma Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global INF-α Consumption and Growth Rate (2017-2022)
-
9.1.2 Global IL-6 Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Rituximab Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Other Consumption and Growth Rate (2017-2022)
-
9.2 Global Immunotherapy Drugs for Multiple Myeloma Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Drug Center Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Other Consumption and Growth Rate (2017-2022)
10 Global Immunotherapy Drugs for Multiple Myeloma Market Outlook by Types and Applications to 2028
-
10.1 Global Immunotherapy Drugs for Multiple Myeloma Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global INF-α Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global IL-6 Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Rituximab Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Other Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Immunotherapy Drugs for Multiple Myeloma Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Drug Center Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Other Consumption Forecast and Growth Rate (2022-2028)
11 Global Immunotherapy Drugs for Multiple Myeloma Import and Export Analysis (Top 5 Countries)
-
11.1 Global Immunotherapy Drugs for Multiple Myeloma Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Immunotherapy Drugs for Multiple Myeloma Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Immunotherapy Drugs for Multiple Myeloma Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Immunotherapy Drugs for Multiple Myeloma Market Competitive Analysis
-
14.1 Sumitomo
-
14.1.1 Sumitomo Company Details
-
14.1.2 Sumitomo Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Sumitomo Immunotherapy Drugs for Multiple Myeloma Product and Service
-
14.2 Roche
-
14.2.1 Roche Company Details
-
14.2.2 Roche Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Roche Immunotherapy Drugs for Multiple Myeloma Product and Service
-
14.3 Schering-Plough
-
14.3.1 Schering-Plough Company Details
-
14.3.2 Schering-Plough Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Schering-Plough Immunotherapy Drugs for Multiple Myeloma Product and Service
-
14.4 Merck
-
14.4.1 Merck Company Details
-
14.4.2 Merck Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Merck Immunotherapy Drugs for Multiple Myeloma Product and Service
-
14.5 Tonghua Dongbao Pharmaceutical
-
14.5.1 Tonghua Dongbao Pharmaceutical Company Details
-
14.5.2 Tonghua Dongbao Pharmaceutical Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Tonghua Dongbao Pharmaceutical Immunotherapy Drugs for Multiple Myeloma Product and Service
-
14.6 Chiron
-
14.6.1 Chiron Company Details
-
14.6.2 Chiron Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Chiron Immunotherapy Drugs for Multiple Myeloma Product and Service
-
14.7 Glaxo
-
14.7.1 Glaxo Company Details
-
14.7.2 Glaxo Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Glaxo Immunotherapy Drugs for Multiple Myeloma Product and Service
-
14.8 Biogen
-
14.8.1 Biogen Company Details
-
14.8.2 Biogen Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Biogen Immunotherapy Drugs for Multiple Myeloma Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Immunotherapy Drugs for Multiple Myeloma
-
Figure Immunotherapy Drugs for Multiple Myeloma Picture
-
Table Global Immunotherapy Drugs for Multiple Myeloma Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Immunotherapy Drugs for Multiple Myeloma Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Immunotherapy Drugs for Multiple Myeloma Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Immunotherapy Drugs for Multiple Myeloma Consumption by Country (2017-2022)
-
Figure United States Immunotherapy Drugs for Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Table Europe Immunotherapy Drugs for Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure China Immunotherapy Drugs for Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure Japan Immunotherapy Drugs for Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure India Immunotherapy Drugs for Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure South Korea Immunotherapy Drugs for Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure Global Immunotherapy Drugs for Multiple Myeloma Consumption Forecast by Country (2022-2028)
-
Figure United States Immunotherapy Drugs for Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Immunotherapy Drugs for Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Immunotherapy Drugs for Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Immunotherapy Drugs for Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Immunotherapy Drugs for Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Immunotherapy Drugs for Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global INF-α Consumption and Growth Rate (2017-2022)
-
Figure Global IL-6 Consumption and Growth Rate (2017-2022)
-
Figure Global Rituximab Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Drug Center Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global INF-α Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global IL-6 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Rituximab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Drug Center Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Immunotherapy Drugs for Multiple Myeloma Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Immunotherapy Drugs for Multiple Myeloma Export by Region (Top 5 Countries) (2017-2028)
-
Table Sumitomo (Foundation Year, Company Profile and etc.)
-
Table Sumitomo Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sumitomo Immunotherapy Drugs for Multiple Myeloma Product and Service
-
Table Roche (Foundation Year, Company Profile and etc.)
-
Table Roche Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Immunotherapy Drugs for Multiple Myeloma Product and Service
-
Table Schering-Plough (Foundation Year, Company Profile and etc.)
-
Table Schering-Plough Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
Table Schering-Plough Immunotherapy Drugs for Multiple Myeloma Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Immunotherapy Drugs for Multiple Myeloma Product and Service
-
Table Tonghua Dongbao Pharmaceutical (Foundation Year, Company Profile and etc.)
-
Table Tonghua Dongbao Pharmaceutical Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
Table Tonghua Dongbao Pharmaceutical Immunotherapy Drugs for Multiple Myeloma Product and Service
-
Table Chiron (Foundation Year, Company Profile and etc.)
-
Table Chiron Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
Table Chiron Immunotherapy Drugs for Multiple Myeloma Product and Service
-
Table Glaxo (Foundation Year, Company Profile and etc.)
-
Table Glaxo Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
Table Glaxo Immunotherapy Drugs for Multiple Myeloma Product and Service
-
Table Biogen (Foundation Year, Company Profile and etc.)
-
Table Biogen Immunotherapy Drugs for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biogen Immunotherapy Drugs for Multiple Myeloma Product and Service
-
